Sanofi (SAN FP) Japan announced on the 21st that it would postpone the launch of its high-dose influenza vaccine for the elderly, "Efluerda.", reports Nikkei
- It was planned to be included in the routine vaccination schedule for those aged 75 and over from October 1st, but its introduction this fall has been postponed.
- Initially, a launch around fall was anticipated. Sanofi Japan explained that "establishing and verifying some manufacturing processes at our domestic contract manufacturer is taking longer than expected," adding that "this will not affect its effectiveness or safety."
- There will be no impact on Efluerda supplied outside of Japan. Efluerda is an influenza preventative vaccine approved in Japan for those aged 60 and over in 2024.
Context
The postponement of Sanofi's high-dose influenza vaccine launch in Japan potentially signals delays in critical product rollouts, which could affect market perceptions of Sanofi's operational efficiency. While the company assures that this will not affect the vaccine's effectiveness or safety, the timing could impact sales forecasts and investor sentiment in the short term. Watch how this might influence sentiment toward the broader pharmaceutical sector, particularly in Asia.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#FRANCE#EUROPE#SANOFI#SAN.FP#BANCO SANTANDER SA#EQUITIES#METALS#EU SESSION#US SESSION#COMMODITIES#PHARMACEUTICALS#DIVERSIFIED BANKS#METALS & MINING#PHARMACEUTICALS (GROUP)#BANKS#MATERIALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#BANKS (GROUP)#SAN#EURO STOXX 50#CAC 40 INDEX#SANOFI SA#CAC